

RC48
G001

Looking for a research study targeting bladder cancer?

Learn more about the **RC48G001 Study** from your doctor

The RC48G001 Study is enrolling participants to learn if the investigational drug (disitamab vedotin) works to treat bladder cancer when it is used alone and when it is used in combination with an anticancer drug (Keytruda).

You may be eligible for the RC48G001 Study if:

- + You are age 18 or older
- + You have been diagnosed with bladder cancer
- + The cancer has spread to nearby tissue or other parts of the body

If you are interested in joining the study, the study doctor or staff will assess you to see if you meet further eligibility criteria.

The use of disitamab vedotin in this study is experimental. Because of that, not all risks are known. It is also not known if it will work in treating bladder cancer. This is why we are conducting the study.

Learn more about the RC48G001 Study

To learn more, call the Seagen Trial Information Hotline at 866-333-7436 or contact our study team today.



<http://www.clinicaltrials.seagen.com/study/?pid=RC48G001>

